DK1150678T3 - Anvendelse af 3-hydroxy-3-methylglutarylcoenzym A-reduktaseinhibitorer til fremstillingen af et medikament til behandlingen af diabetisk neuropati - Google Patents

Anvendelse af 3-hydroxy-3-methylglutarylcoenzym A-reduktaseinhibitorer til fremstillingen af et medikament til behandlingen af diabetisk neuropati

Info

Publication number
DK1150678T3
DK1150678T3 DK00901744T DK00901744T DK1150678T3 DK 1150678 T3 DK1150678 T3 DK 1150678T3 DK 00901744 T DK00901744 T DK 00901744T DK 00901744 T DK00901744 T DK 00901744T DK 1150678 T3 DK1150678 T3 DK 1150678T3
Authority
DK
Denmark
Prior art keywords
medicament
hydroxy
manufacture
treatment
reductase inhibitors
Prior art date
Application number
DK00901744T
Other languages
English (en)
Inventor
Norman E Cameron
Mary A Cotter
Original Assignee
Astrazeneca Ab
Univ Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9902591.8A external-priority patent/GB9902591D0/en
Priority claimed from GBGB9902594.2A external-priority patent/GB9902594D0/en
Application filed by Astrazeneca Ab, Univ Aberdeen filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1150678T3 publication Critical patent/DK1150678T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK00901744T 1999-02-06 2000-02-01 Anvendelse af 3-hydroxy-3-methylglutarylcoenzym A-reduktaseinhibitorer til fremstillingen af et medikament til behandlingen af diabetisk neuropati DK1150678T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9902591.8A GB9902591D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
GBGB9902594.2A GB9902594D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
PCT/GB2000/000280 WO2000045818A1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy

Publications (1)

Publication Number Publication Date
DK1150678T3 true DK1150678T3 (da) 2007-10-08

Family

ID=26315085

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00901744T DK1150678T3 (da) 1999-02-06 2000-02-01 Anvendelse af 3-hydroxy-3-methylglutarylcoenzym A-reduktaseinhibitorer til fremstillingen af et medikament til behandlingen af diabetisk neuropati
DK07008956.0T DK1897546T3 (da) 1999-02-06 2000-02-01 Kombinerede sammensætninger omfattende (E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s]-3,5-dihydroxyhept-6-enoinsyre

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07008956.0T DK1897546T3 (da) 1999-02-06 2000-02-01 Kombinerede sammensætninger omfattende (E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s]-3,5-dihydroxyhept-6-enoinsyre

Country Status (34)

Country Link
US (4) US6894058B1 (da)
EP (2) EP1897546B1 (da)
JP (3) JP2002536332A (da)
KR (1) KR100699757B1 (da)
CN (1) CN1196488C (da)
AR (1) AR025512A1 (da)
AT (2) ATE485823T1 (da)
AU (1) AU763970B2 (da)
BR (1) BR0007996A (da)
CA (1) CA2368186C (da)
CY (2) CY1106879T1 (da)
CZ (2) CZ302893B6 (da)
DE (2) DE60035575T2 (da)
DK (2) DK1150678T3 (da)
EE (2) EE05556B1 (da)
ES (2) ES2286995T3 (da)
GB (1) GB0001662D0 (da)
HK (2) HK1041223A1 (da)
HU (1) HU227642B1 (da)
IL (3) IL144730A0 (da)
IS (2) IS2793B (da)
MX (1) MXPA01007821A (da)
MY (1) MY138289A (da)
NO (1) NO330400B1 (da)
NZ (3) NZ536433A (da)
PL (1) PL198098B1 (da)
PT (2) PT1150678E (da)
RU (1) RU2239456C2 (da)
SI (2) SI1897546T1 (da)
SK (2) SK286854B6 (da)
TR (1) TR200102229T2 (da)
TW (1) TWI230067B (da)
WO (1) WO2000045818A1 (da)
ZA (1) ZA200105885B (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US20030060488A1 (en) * 2000-02-10 2003-03-27 Yasuo Sugiyama Drug comprising combination
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
DE10025308A1 (de) * 2000-05-23 2001-11-29 Bayer Ag Kombination von Cerivastatin mit ACE Inhibitoren und ihre Verwendung in Arzneimitteln
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
PE20020323A1 (es) * 2000-08-22 2002-06-13 Novartis Ag COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)
ZA200302507B (en) * 2000-10-12 2004-03-31 Nisaan Chemical Ind Ltd Preventives and remedies for complications of diabetes.
AU2001276645A1 (en) * 2000-10-18 2002-04-29 Pfizer Products Inc. Combination of statins and sorbitol dehydrogenase inhibitors
AU2002215160A1 (en) * 2000-11-30 2002-06-11 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
US20030199424A1 (en) * 2002-03-20 2003-10-23 Smith Maree Therese Method of treatment and/or prophylaxis
TW200810743A (en) * 2002-03-22 2008-03-01 Novartis Ag Combination of organic compounds
JP4395633B2 (ja) * 2002-08-29 2010-01-13 学校法人鈴鹿医療科学大学 非神経細胞の神経細胞への分化成熟法、該組成物と該組成物探索法
DE10302452B4 (de) * 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
AU2004233693B2 (en) * 2003-04-28 2007-07-19 Funahashi, Toru Adiponectin production enhancer
JP2005232151A (ja) * 2003-04-28 2005-09-02 Iichiro Shimomura 糖取り込み能増強剤
WO2004096276A1 (ja) * 2003-04-28 2004-11-11 Sankyo Company, Limited 糖取り込み能増強剤
US20090082407A1 (en) * 2004-06-18 2009-03-26 Biostratum, Inc. Pyridoxamine for the Treatment of Diabetic Kidney Disease
EP1643999B8 (en) * 2003-06-20 2012-03-14 NephroGenex, Inc. Pyridoxamine for use in the treatment of diabetic nephropathy in type ii diabetes
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
AU2003269484A1 (en) * 2003-09-11 2005-03-29 Biocon Limited Salt of atorvastatin with metformin
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
AU2003272084A1 (en) * 2003-10-07 2005-04-21 Biocon Limited SALT OF 1,2,6,7,8,8A-HEXAHYDRO-Beta,Delta,6-TRIHYDROXY-2-METHYL-8-((2S)-2-METHYL-1-OXOBUTOXY)-, (BetaR,Delta R,1S,2S,6S,8S,8AR)- 1-NAPHTHALENEHEPTANOIC ACID WITH N,N-DIMETHYL-IMIDODICARBONIMIDIC DIAMIDE
KR100715114B1 (ko) * 2005-02-19 2007-05-10 한국유나이티드제약 주식회사 당뇨병 치료를 위한 약학적 조성물
CN101632673B (zh) * 2008-07-24 2011-08-10 鲁南制药集团股份有限公司 含有氯沙坦、吡格列酮和瑞舒伐他汀的药物组合物及其新用途
US8906948B2 (en) 2008-09-06 2014-12-09 Bionevia, LLC Choline cocrystal of epalrestat
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
RU2014124118A (ru) 2011-11-15 2015-12-27 Др. Редди'С Лабораторис Лтд. Фармацевтические препараты, включающие аторвастатин и глимепирид
WO2015053589A1 (ko) * 2013-10-11 2015-04-16 가톨릭대학교 산학협력단 메트포민 및 스타틴의 복합제를 이용한 자가면역질환의 예방 또는 치료용 조성물
KR101579656B1 (ko) * 2013-12-12 2015-12-22 가천대학교 산학협력단 프라바스타틴과 발사르탄을 포함하는 약학 조성물
CN110747206B (zh) * 2019-11-05 2021-11-23 昆明理工大学 3-羟基-3-甲基戊二酸单酰辅酶a还原酶基因rkhmgr及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5190970A (en) 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9208116D0 (en) * 1992-04-13 1992-05-27 Ici Plc Therapeutic agents
DK0636027T3 (da) 1992-04-13 2000-01-31 Zeneca Ltd Angiotensin-II-antogonister mod sygdomme forbundet med forringet neuronal ledningshastighed, især diabetisk neuropati
AU1095695A (en) 1993-11-09 1995-05-29 Brigham And Women's Hospital Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction
CA2186606A1 (en) 1994-03-29 1995-10-05 Edward B. Nelson Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
SI0914158T2 (sl) 1996-04-05 2006-04-30 Takeda Chemical Industries Ltd Farmacevtska kombinacija, ki vsebuje spojino z angiotenzin II-antagonisticno aktivnostjo in spojino, ki povecuje inzulinsko obcutljivost
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6262076B1 (en) * 2000-01-28 2001-07-17 Ajinomoto Co., Inc. Pharmaceutical composition for use in the treatment of diabetic neuropathy
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment

Also Published As

Publication number Publication date
ES2352803T3 (es) 2011-02-23
GB0001662D0 (en) 2000-03-15
AU763970B2 (en) 2003-08-07
AU2304700A (en) 2000-08-25
EP1150678A1 (en) 2001-11-07
IL208330A0 (en) 2010-12-30
RU2239456C2 (ru) 2004-11-10
DE60035575T2 (de) 2008-04-03
MXPA01007821A (es) 2004-08-19
HUP0105138A2 (hu) 2002-04-29
CA2368186C (en) 2008-06-03
JP2002536332A (ja) 2002-10-29
CZ302893B6 (cs) 2012-01-11
SK287792B6 (sk) 2011-10-04
EP1897546B1 (en) 2010-10-27
ATE485823T1 (de) 2010-11-15
US20050209128A1 (en) 2005-09-22
NO20013812L (no) 2001-10-02
MY138289A (en) 2009-05-29
IL144730A (en) 2010-12-30
WO2000045818A1 (en) 2000-08-10
PL350312A1 (en) 2002-12-02
IS6016A (is) 2001-07-20
AR025512A1 (es) 2002-12-04
HK1041223A1 (en) 2002-07-05
PL198098B1 (pl) 2008-05-30
SK286854B6 (sk) 2009-06-05
CZ302881B6 (cs) 2012-01-04
EP1150678B1 (en) 2007-07-18
SK11102001A3 (sk) 2002-05-09
EE201200015A (et) 2012-10-15
NZ525419A (en) 2004-12-24
NZ513061A (en) 2003-06-30
ATE367162T1 (de) 2007-08-15
EE05621B1 (et) 2013-02-15
HK1118209A1 (en) 2009-02-06
CY1110992T1 (el) 2015-06-11
PT1897546E (pt) 2010-12-15
IS2793B (is) 2012-08-15
EP1897546A1 (en) 2008-03-12
EE05556B1 (et) 2012-08-15
DE60045168D1 (de) 2010-12-09
HU227642B1 (en) 2011-10-28
EE200100405A (et) 2002-10-15
SI1897546T1 (sl) 2011-02-28
IS8978A (is) 2011-08-23
PT1150678E (pt) 2007-09-14
ES2286995T3 (es) 2007-12-16
KR20010089635A (ko) 2001-10-06
BR0007996A (pt) 2001-10-30
IS2820B (is) 2012-12-15
CA2368186A1 (en) 2000-08-10
NZ536433A (en) 2006-08-31
JP2014065718A (ja) 2014-04-17
NO330400B1 (no) 2011-04-04
CZ20012806A3 (cs) 2002-02-13
CN1338937A (zh) 2002-03-06
US20120041010A1 (en) 2012-02-16
TR200102229T2 (tr) 2001-12-21
KR100699757B1 (ko) 2007-03-27
CN1196488C (zh) 2005-04-13
ZA200105885B (en) 2002-10-17
IL144730A0 (en) 2002-06-30
DE60035575D1 (de) 2007-08-30
HUP0105138A3 (en) 2002-11-28
NO20013812D0 (no) 2001-08-03
US20090186908A1 (en) 2009-07-23
US6894058B1 (en) 2005-05-17
CY1106879T1 (el) 2012-05-23
SI1150678T1 (sl) 2008-02-29
DK1897546T3 (da) 2011-01-17
TWI230067B (en) 2005-04-01
JP2012051898A (ja) 2012-03-15

Similar Documents

Publication Publication Date Title
DK1150678T3 (da) Anvendelse af 3-hydroxy-3-methylglutarylcoenzym A-reduktaseinhibitorer til fremstillingen af et medikament til behandlingen af diabetisk neuropati
DK1373259T3 (da) Pyridazinonaldosereduktaseinhibitorer
ATE258928T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
ATE259796T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
DE60324099D1 (de) Arzneistoffhaltiger tampon
BR0001826B1 (pt) fralda descartÁvel.
DE60312780D1 (de) Wegwerfwindel
DE60236093D1 (de) Entfernbarer stent
BR0106049B1 (pt) fralda descartÁvel.
DE60043764D1 (de) Wegwerfwindel
DE60037479D1 (de) Absorbierender Wegwerfartikel
DE60040308D1 (de) Absorbierender Wegwerfartikel
DE60012111D1 (de) Absorbierender Wegwerfartikel
EE200300239A (et) Rosuvastatiini (ZD4522) kasutamine heterosügootseperekondliku hüperkolesteroleemia raviks
DE60203429D1 (de) Absorbierender Wegwerfartikel
DE60018509D1 (de) Wegwerfwindel
DE60022437D1 (de) Wegwerfwindel
BR0300396B1 (pt) artigo absorvente higiÊnico.
DE60040712D1 (de) Wegwerfwindel
BR0103960B1 (pt) fralda descartável.
DE60024528D1 (de) Wegwerfwindel
DE60030399D1 (de) Wegwerfwindel
DE60019848D1 (de) Absorbierender Wegwerfartikel
BR0000706B1 (pt) fralda descartÁvel.
DE60025453D1 (de) Wegwerfwindel